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OVERCOMING LOGISTICAL CHALLENGES IN PERFORMING INTERVEN-
TIONAL CLINICAL TRIALS IN THE LONG-TERM FOLLOW-UP (LTFU)
SETTING AFTER HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Dahlgren, C.J., Nguyen, H.-L., Choe, P., Boeckh, M. Fred Hutchinson
Cancer Research Center, Seattle, WA.
Background: Conducting interventional clinical trials according
to Good Clinical Practice (GCP) standards presents a formidable
challenge in the LTFU period following HCT. Challenges include
receiving blood specimens promptly from patients living in remote
locations, gaining patient and provider commitment to regular lab
testing and clinical assessments, and maintaining timely commu-
nication between providers and patients for clinical interventions.
Methods: We evaluated logistical aspects of conducting an inter-
ventional clinical trial in the LTFU setting. Data from a multi-
center, randomized placebo-controlled trial for prevention of late
CMV complications were examined for: geographic distribution of
patient location, feasibility of overnight shipment of specimens,
and time to appropriate intervention following results. Clinical
interventions consisted of (a) start of preemptive antiviral treat-
ment for positive CMV quantitative PCR result (b) interruption of
study drug administration and start of GCSF for any neutropenic
episode deﬁned by ANC1.000/uL and (c) adjusting dose of study
medication based on renal function. The study included 8 partic-
ipating sites. All samples were analyzed at FHCRC, the central site.
Results: 140 study participants were distributed over 112 cities and
36 states including Alaska. We received 3661 blood specimens
(90% were collected at off-site locations). From the time each
specimen was sent by overnight carrier, 85% were received by the
central site in 24 hours, 9% were received between 24-48 hours,
and 6% were received	48 hours. Treatment for CMV began after
a median of 1 (range 0-7) day(s) after the PCR result was obtained.
Upon report of the CMV PCR result to the provider, 26% of
patients were treated on the same day, 37% within 1 day, 26%
within 2 days, and 11% within 3 days. The median time from
awareness of neutropenia to holding study drug was 0 (range 0-3)
days; 81% of the patients held study drug on the same day of the
result, 5% within 1 day, 11% within 2 days, and 3% within 3 days.
Dose adjustment for renal function was implemented a median of
1 (range 0-2) day(s) upon obtaining the result. Of these renal
adjustments, 2% occurred on the same day, 95% within 1 day, and
3% within 2 days. Conclusions: This study demonstrates that
complex interventional randomized studies in the LTFU setting
are feasible, even if most participants live in distant locations, and
that therapeutic decisions can be made on a real-time basis.
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QUALITY OF LIFE, SPIRITUAL WELL-BEING, AND SURVIVAL POST-
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Morris, M.E., Lynch, J.C., Bociek, G., Bierman, P.J., Vose, J.M.,
Armitage, J.O. University of Nebraska Medical Center, Omaha, NE.
Introduction: Quality of life (QOL) is an important outcome in
the treatment of malignancy, including hematopoietic stem cell
transplant (HSCT). QOL is conceptualized as multi-dimensional
including physical, psychosocial, emotional, and spiritual well-
being (SWB). Purpose: A longitudinal QOL study of post-HSCT
recipients is being conducted at the University of Nebraska Med-
ical Center (UNMC) to evaluate changes over time in QOL and to
examine the relationship between patient, disease, and transplant
characteristics and QOL. Methods: Participants complete the
Medical Outcomes Survey SF-36, Functional Assessment of Can-
cer Therapy-Bone Marrow Transplant (FACT-BMT), and City of
Hope (COH) Medical Center-BMT survivor questionnaires at
baseline (pre-HSCT), day 100, and yearly post-HSCT. For each
subscale, the sample was dichotomized as 80th percentile ver-
sus 	 80th percentile of the baseline score, and clinical outcomes
compared between the two groups. Results of the baseline COH
SWB subscale, which includes questions regarding uncertainty,
purpose, hope, and peace, are reported here. Results: Between
September 2001 and June 2004, 172 participants received autolo-
gous HSCT for hematologic malignancy. Most (97%) were white,
non-Hispanic, 55% were male, and the median age at transplant
was 52 years (range 20-75). Median follow-up of surviving patients
is 24 months (range 12-49) and 44 (25%) patients had progressed
prior to analysis. The 3 year overall survival (OAS) rate for patients
with high (	9.0) SWB was 93% compared to 79% for patients
with lower SWB (P  .05, log rank test). However, baseline SWB
was not a statistically signiﬁcant predictor for event-free survival or
relapse rate. No other COH subscale scores were signiﬁcantly
related to clinical outcome nor were any FACT subscale scores.
Discussion: In this initial analysis, SWB at baseline is a signiﬁcant
predictor of OAS. Multivariate analysis is needed to determine if
the impact of SWB can be explained by other patient characteris-
tics such as co-morbidities or disease status at HSCT. Implica-
tions: Additional studies focusing on longitudinal spiritual assess-
ment and intervention are needed to determine the long-term
impact of SWB on QOL and survival.
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DOES IT MATTER WHEN A PATIENT IS REFERRED FOR INITIAL CON-
SULT FOR BLOOD AND MARROW TRANSPLANT
Campbell, S.W., Dale, I.L., Lyons, P.A., Tate, D.F. University of
Alabama at Birmingham (UAB) BMT Program, Birmingham, AL.
As data manager and bone marrow transplant coordinators at the
University of Alabama at Birmingham (UAB) Bone marrow Trans-
plant (BMT) Program, we are constantly seeking ways to help
facilitate better patient outcomes. We, as a group, asked the ques-
tion “Does it really matter when a patient is referred for blood and
marrow transplant?” A retrospective analysis of 45 patients with
hematological malignancies was done evaluating the appropriate-
ness of the time frame from diagnosis of disease to the initial
consultation with the BMT team and the overall outcomes based
upon the recommendations from the National Comprehensive
Cancer Network (NCCN) Guidelines. Of these 45 patients, 14
were deemed appropriate or early referrals, and 31 were deﬁned as
late for initial consultation with the BMT team during the 2004
calendar year. Fifty percent of the early referrals and 35% of the
late referrals (18 patients total) went on to receive a HSCT. There
were numerous reasons why the 27 patients failed to receive a
HSCT, some of which include patient choice, disease relapse, and
co-morbid conditions. Of the 18 patients who did receive a trans-
plant, 11 of those patients are still alive and well today. Overall,
based upon guidelines from the NCCN, our data supports early
referral versus late referral.
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WASHINGTON UNIVERSITY NURSING EXPERIENCE COORDINATING
PATIENT CARE ON A PHASE III TRIAL EVALUATING AMD3100 (MOZO-
BILTM), A NOVEL DRUG FOR STEM CELL MOBILIZATION
Devine, H., Larson, S., Comer, H. Barnes-Jewish Hospital/Washington
University Medical Center in St. Louis, St. Louis, MO.
AMD3100 (MOZOBILTM) is a novel agent which induces a
rapid increase in the number of stem cells in peripheral blood. It
appears to be safe and when combined with G-CSF may increase
the yield of stem cells compared to G-CSF alone. The optimum
mobilization occurs when the drug is scheduled the evening prior
to apheresis, creating a number of potential logistical difﬁculties
managing trials evaluating this agent. As we commenced accrual to
a phase III placebo controlled study comparing G-CSF alone to its
combination with MOZOBIL, we worked diligently to ensure
there were no gaps in patient care. Patient teaching strategies
included verbal instruction contrasting historical methods of stem
cell mobilization with this novel procedure as well as printed BMT
literature. All patients and their caregivers were offered involve-
ment in a patient education class. The RN coordinator was instru-
mental in creating the patient’s mobilization schema and further
collaborating with the clinical research associate, apheresis depart-
ment, stem cell laboratory, and the inpatient and outpatient treat-
ment areas. Since our medical center does not have an after hours
outpatient clinic, our patients received MOZOBIL/placebo on a
designated inpatient unit. Challenges with this approach occurred
when the inpatient unit was understaffed or had high acuity pa-
tients. Additionally, the inpatient RNs expressed concern regard-
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